6.KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na KIM ; Ji Won HAN ; Jihyun AN ; Beom Kyung KIM ; Young-Joo JIN ; Seung-seob KIM ; Minjong LEE ; Han Ah LEE ; Yuri CHO ; Hee Yeon KIM ; Yu Rim SHIN ; Jung Hwan YU ; Moon Young KIM ; YoungRok CHOI ; Young Eun CHON ; Eun Ju CHO ; Eun Joo LEE ; Sang Gyune KIM ; Won KIM ; Dae Won JUN ; Seung Up KIM ;
Clinical and Molecular Hepatology 2024;30(suppl):s5-s105
7.Clinical Significance of Epstein-Barr Virus and Helicobacter pylori Infection in Gastric Carcinoma
Jin Hee NOH ; Jun Young SHIN ; Jeong Hoon LEE ; Young Soo PARK ; In-Seob LEE ; Ga Hee KIM ; Hee Kyong NA ; Ji Yong AHN ; Kee Wook JUNG ; Do Hoon KIM ; Kee Don CHOI ; Ho June SONG ; Gin Hyug LEE ; Hwoon-Yong JUNG
Gut and Liver 2023;17(1):69-77
Background/Aims:
Epstein-Barr virus (EBV) and Helicobacter pylori (HP) coinfection may synergistically induce severe inflammatory responses in the stomach tissue, increasing the risk of developing gastric cancer. We aimed to analyze the effect of EBV and HP coinfection on the clinicopathologic features and prognosis of gastric cancer, as well as to evaluate the role of EBV infection in non-gastric carcinoma with lymphoid stroma (non-GCLS).
Methods:
Overall, 956 patients who underwent surgery for gastric cancer between September 2014 and August 2015 were eligible and divided into groups, according to GCLS morphology, EBV infection, and HP infection. Clinicopathologic characteristics and oncologic outcomes were analyzed retrospectively.
Results:
EBV and HP coinfection was significantly associated with male sex, proximal location, GCLS morphology, and equivocal p53 expression (p<0.001). Multivariate analysis revealed that EBV infection alone (hazard ratio [HR], 0.362; 95% CI, 0.131 to 0.996; p=0.049) and lower third location (HR, 0.624; 95% CI, 0.413 to 0.943; p=0.025) were inversely correlated with overall survival. During median follow-up period of 72 months, overall survival rate was not significantly different between the EBV and HP coinfection group and others (97.6% vs 86.8%, log-rank p=0.144). In non-GCLS patients (n=920), overall survival rate was not significantly different between the EBV infection group and others (96.9% vs 86.4%, log-rank p=0.126).
Conclusions
EBV and HP coinfection is not an independent prognostic factor for gastric cancer. EBV infection status, regardless of HP infection, affects the clinicopathologic features of all types of gastric cancer. However, it does not lead to a significant difference in overall survival of nonGCLS patients.
9.Multi-Institute, Single Group, Prospective Observational Study to Evaluate the Efficacy of Mucomyst® in Relieving Symptoms of Globus Pharyngeus Refractory to Proton Pump Inhibitor
Hannah PARK ; Il-Seok PARK ; Sang Hyuk LEE ; Seung-Won LEE ; Sang Joon LEE ; Byung-Joo LEE ; Yong-Il CHEON ; Jun-Ook PARK ; Kyoung Ho OH ; Yoo Seob SHIN
Journal of the Korean Society of Laryngology Phoniatrics and Logopedics 2022;33(1):20-25
Background and Objectives:
Globus pharyngeus is one of the most common symptoms of patients visiting otorhinolaryngology out-patient clinic, and usually long-lasting, difficult to treat, and frequently recurrent. Mucomyst®, N-acetyl cysteine is an inhalation agent mainly used for mucolysis and reducing inflammation in airway via antioxidative effect. The purpose of this study was to evaluate the efficacy of inhaled Mucomyst® treatment in patients with globus pharyngeus refractory to proton pump inhibitor (PPI).Materials and Method We prospectively evaluated the efficacy of Mucomyst® in relieving symptoms of globus pharyngeus refractory to PPI in nine medical centers. Three hundred and three patients enrolled and finally 229 patients finished the inhaled Mucomyst® therapy for 8 weeks. We analyzed the change of Reflux Symptom Index (RSI), Reflux Finding Score (RFS), Visual Analogue Scale (VAS) for globus, and Globus Pharyngeus Symptom Scale (GPS) after use of Mucomyst® for 4 and 8 weeks.
Results:
The GPS, RSI, RFS, and VAS score significantly decreased serially in patients who finished 8 week-inhalation treatment. The GPS improvement gap was significantly correlated with initial GPS (p<0.001) in multiple regression analysis.
Conclusion
Inhaled Mucomyst® therapy was effective for the reduction of both subjective and objective findings in refractory globus patients. This study might suggest new treatment option for patients with globus. However, further thorough studies would be needed to assess the real effect of inhaled Mucomyst® treatment as a standard treatment for globus.
10.Meningioma Originating From Choroid Plexus of Foramen of Luschka: A Rare Case Report and Tip of Differential Diagnosis
Yong-Jun LEE ; Bo-Seob KIM ; Yeong Jin KIM ; Kyung-Hwa LEE ; Shin JUNG
Brain Tumor Research and Treatment 2022;10(4):265-269
Meningiomas are the most common benign brain tumors, and most of them originate from the dura mater. However, in some cases, they can originate from the choroid plexus, and they are rarely found in the posterior cranial fossa. A 63-year-old female patient presented with dizziness and swallowing difficulty and was found to have a homogeneously enhancing mass in the right posterior cranial fossa. Mass removal was performed through retrosigmoid suboccipital craniotomy, and the mass was confirmed to originate from the choroid plexus. The pathological diagnosis was meningothelial meningioma. The patient had temporary swallowing difficulty but recovered without any neurological sequelae. We report a rare case of a lower cerebellopontine angle meningioma without dural attachment originating from the choroid plexus of the foramen of Luschka.

Result Analysis
Print
Save
E-mail